StockData
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. (TNYA) stock

TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$0.32−0.01 (-3.24%)

Close on Nov 17, 2026Market cap $72.38MP/E –Yield –

Earnings

Tenaya Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 10, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$1.70M
EPS, Q3 FY2026
-$0.08
-$0.12 a year earlier
Latest guidance
Issued
May 7, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of Tenaya Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 10, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$1.70M–-$0.08Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close$225.00K–-$0.09Release
Q4 FY2025ended Dec 31, 2025Mar 11, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025before the open––-$0.12Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close––-$0.14Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 10, 2025after the close––-$0.28Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close––-$0.30Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close––-$0.34Release
Q1 FY2024ended Mar 31, 2024May 14, 2024after the close––-$0.40Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Tenaya Therapeutics guided for has been reported

Guidance history

Every forecast Tenaya Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
May 7, 2025aggregate charges, primarily related to employee cash severance and continuing health benefitsQ3 FY2025$1.60M – $2.70MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Tenaya Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Update
  7. Update
  8. Update
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Update
  15. Update

See a number that looks wrong?